证券代码：600479 证券简称：千金药业 公告编号：2023-032 株洲千金药业股份有限公司 2023 年半年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上市公司行业信息披露指引第六号——医药制造（2022 年修订）》及《关于做好主板上市公司 2023 年半年度报告披露工作 的通知》的要求，公司现将 2023 年半年度主要经营数据披露如 下： 一、报告期内公司主营业务分行业经营情况 单位：元 币种：人民币 | | | | | 营业 | 营业 | | | --- | --- | --- | --- | --- | --- | --- | | | | | | 收入 | 成本 | 毛利率 | | | | | 毛利 | 比上 | 比上 | 比上年 | | 分行业 | 营业收入 | 营业成本 | 率 | 年同 | 年同 | 同期增 | | | | | （%） | 期增 | 期增 | 减（%） | | | | | | 减 | 减 | | | | | | | （%） | （%） | | | 药品生 | ...

株洲千金药业股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 证券代码：600479 证券简称：千金药业 公告编号：2023-020 二、 说明会召开的时间、地点 （一） 会议召开时间：2023 年 06 月 01 日 下午 16:00-17:00 （二） 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） （三） 会议召开方式：上证路演中心网络互动 http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 25 日(星期四) 至 05 月 31 日(星期 三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 qjyydb@qjyy.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 株洲千金药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 13 日发布公司 20 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 960,198,380.73, representing a year-on-year increase of 0.78%[5] - The net profit attributable to shareholders for the same period was CNY 43,906,688.63, reflecting a growth of 9.83% compared to the previous year[5] - The basic earnings per share for Q1 2023 was CNY 0.1021, which is an increase of 9.78% year-on-year[6] - Net profit for Q1 2023 reached CNY 56,747,393.26, representing a 11.8% increase from CNY 51,053,482.14 in Q1 2022[22] - Earnings per share (EPS) for Q1 2023 was CNY 0.1021, up from CNY 0.0930 in Q1 2022, indicating a growth of 11.7%[22] - Operating profit for Q1 2023 was CNY 66,059,069.40, an increase of 10.0% compared to CNY 60,011,882.13 in Q1 2022[22] - The total comprehensive income for Q1 2023 was CNY 56,747,616.03, compared to CNY 51,057,662.72 in Q1 2022, indicating a growth of 11.1%[22] Cash Flow - The net cash flow from operating activities was negative at CNY -194,039,475.06, a decline of 117.95% compared to the previous year[5] - In Q1 2023, the company reported cash inflows from operating activities of CNY 892,443,008.01, a slight increase from CNY 888,763,769.19 in Q1 2022[23] - The net cash flow from operating activities was negative at CNY -194,039,475.06, compared to CNY -89,031,314.87 in the same period last year[23] - Cash inflows from investment activities totaled CNY 673,552,699.43, up from CNY 454,306,953.47 in Q1 2022[24] - The net cash flow from investment activities increased significantly to CNY 353,581,904.39, compared to CNY 105,206,951.54 in the previous year[24] - The company recorded cash inflows from financing activities of CNY 439,200.00, a decrease from CNY 48,590,000.00 in Q1 2022[24] - The net cash flow from financing activities was minimal at CNY 10,325.86, down from CNY 48,036,077.26 in the same quarter last year[24] - The ending balance of cash and cash equivalents increased to CNY 1,263,103,574.11, compared to CNY 574,712,986.35 at the end of Q1 2022[24] - The company’s total cash inflow from sales of goods and services was CNY 845,525,998.14, slightly higher than CNY 833,670,513.80 in Q1 2022[23] - Total cash outflows from operating activities were CNY 1,086,482,483.07, compared to CNY 977,795,084.06 in the previous year[23] Assets and Liabilities - Total assets at the end of Q1 2023 amounted to CNY 4,532,287,499.46, down 1.94% from the end of the previous year[6] - As of March 31, 2023, the total current assets amounted to ¥3,429,983,040.81, a decrease of 2.38% from ¥3,513,491,527.41 on December 31, 2022[15] - The total assets decreased to ¥4,532,287,499.46 from ¥4,621,975,680.77, indicating a decline of 1.93%[16] - Total liabilities decreased to CNY 1,655,459,691.84 in Q1 2023 from CNY 1,805,690,959.18 in Q1 2022, a reduction of approximately 8.3%[21] - The company reported a decrease in total non-current liabilities to CNY 98,930,438.54 in Q1 2023 from CNY 108,469,095.61 in Q1 2022, a decline of approximately 8.5%[21] - Total equity increased to CNY 2,876,827,807.62 in Q1 2023 from CNY 2,816,284,721.59 in Q1 2022, reflecting a growth of about 2.1%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 36,602[12] Other Financial Metrics - The company's weighted average return on equity was 1.96%, an increase of 0.12 percentage points from the previous year[6] - Research and development expenses for Q1 2023 were CNY 23,884,290.27, a decrease of 5.1% from CNY 25,165,661.29 in Q1 2022[21] - Other income for Q1 2023 was CNY 6,753,939.61, significantly higher than CNY 3,157,591.09 in Q1 2022, marking an increase of 114.3%[21] - The company reported a significant increase in other receivables by 314.02%, primarily due to increased advances and guarantees[10] - The company experienced a 69.44% decrease in trading financial assets, mainly due to the redemption of bank structured deposits[10] - The company received government subsidies that contributed to a 113.90% increase in other income[10] - The company reported a significant increase in other receivables, which reached ¥115,239,579.50, compared to ¥27,834,261.03, marking a growth of 313.36%[15] - The company has not disclosed any new product developments or market expansion strategies in the current report[14] - Short-term borrowings decreased to ¥51,539,744.30 from ¥58,131,110.09, a reduction of 10.00%[16] - Accounts payable increased to ¥379,080,960.03, up 19.14% from ¥318,206,420.96[16] - Other payables rose to ¥460,387,086.60, an increase of 19.22% from ¥386,193,457.69[16]

Financial Performance - In 2022, the net profit attributable to the parent company was CNY 303,625,165.42, with a legal surplus reserve of CNY 5,650,000.00, resulting in distributable profits of CNY 297,975,165.42[5] - The total distributable profits available for shareholders reached CNY 970,824,432.66, including retained earnings of CNY 672,849,267.24 from previous distributions[5] - The company reported no significant risks that could materially affect its operations during the reporting period[8] - The company's total revenue for 2022 was approximately ¥4.03 billion, representing a decrease of 9.89% compared to ¥3.66 billion in 2021[23] - Net profit attributable to shareholders was approximately ¥303.63 million, a slight increase of 0.52% from ¥302.06 million in the previous year[23] - Operating cash flow increased significantly by 51.05%, reaching approximately ¥733.47 million, up from ¥485.57 million in 2021[23] - The company's total assets grew by 13.84% year-over-year, reaching approximately ¥4.62 billion compared to ¥4.06 billion at the end of 2021[23] - The weighted average return on equity increased to 13.89%, up from 13.68% in the previous year, indicating improved profitability[24] - The company achieved operating revenue of CNY 4,026,278,593.25, a year-on-year increase of 9.89% from CNY 3,663,844,613.10[52] - The total profit reached CNY 44,581,280, a 2.86% increase compared to CNY 43,342,200 in the previous year[52] Dividend Distribution - The company plans to distribute a cash dividend of CNY 3.5 per 10 shares (tax included) to all shareholders based on the number of shares on the dividend record date[5] - The company has a cash dividend policy that mandates a minimum of 20% of the annual distributable profit to be distributed as cash dividends[171] - In 2021, the company distributed a cash dividend of 6 RMB per 10 shares, totaling 257,884,270.20 RMB, which represents 85.37% of the net profit attributable to ordinary shareholders[174] Risk Management - The company has a comprehensive risk management strategy outlined in the management discussion and analysis section of the report[8] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[6] - The company has not provided guarantees in violation of regulatory decision-making procedures[7] - The audit report issued by Tianzhi International Accounting Firm was a standard unqualified opinion[4] - The company’s financial report is guaranteed for authenticity and completeness by its management team[4] Market Position and Growth - The company maintains a leading position in the domestic women's health pharmaceutical sector, with its flagship product, the "Qianjin" brand, recognized as the first Chinese famous trademark in the gynecological traditional Chinese medicine field[43] - The market share of the gynecological product Qianjin Pian (capsule) in urban retail pharmacies reached 29.3%[33] - The B2C segment experienced a significant growth of 244% year-on-year[33] - The company’s marketing coverage in tiered hospitals increased to 65.3%, with a dual-driven growth model established in the gynecology sector[50] - The market share of the company's gynecological product, Qianjin Female Health, rose from 17.0% in 2017 to 21.8% in 2022[50] Research and Development - The company completed the development of 1 new drug and advanced 2 new drugs in the pipeline[34] - The company’s R&D expenses amounted to CNY 113,821,255.07, a 4.70% increase from the previous year[55] - The company has 33 ongoing traditional Chinese medicine projects, including new drug development and clinical research, with 5 classic formulas completing formulation research[98] - The company is committed to enhancing its research and development efforts to innovate new products and technologies in the pharmaceutical sector[87] - The company has established a medicinal material reserve to mitigate price fluctuations, maintaining relative stability in supply prices[132] Environmental Responsibility - The company invested 4.2 million yuan in environmental protection during the reporting period[184] - The company has established a wastewater treatment facility with a design capacity of 1,500 tons per day at the He Dong plant, operational since 2001[187] - The company has implemented measures to reduce VOC emissions through the use of adsorption towers[188] - The company achieved full compliance in the "2022 Pollutant Discharge Self-Monitoring Joint Assistance Inspection" organized by the Ministry of Ecology and Environment in July 2022[192] - The company has implemented measures to reduce carbon emissions, including the use of clean energy natural gas at both production bases and the initiation of a dust removal project to lower VOC emissions[193] Corporate Governance - The company has a governance structure that complies with relevant laws and regulations, ensuring effective operation and risk management[136] - The board of directors has established specialized committees, including the audit, nomination, compensation, and strategic committees, to enhance governance[158] - The company has not faced any penalties from securities regulatory authorities in the past three years[155] - The company has successfully held multiple shareholder meetings, with all resolutions passed, ensuring shareholder engagement and compliance[140] Employee Management - The total number of employees in the parent company is 1,586, while the total number of employees in major subsidiaries is 3,547, resulting in a combined total of 5,133 employees[165] - The company has implemented a salary system that includes a performance-based component for sales employees, combining a base salary with profit commissions[166] - The company emphasizes employee training and development, implementing customized training programs to align with strategic business needs[168] - The company has established a dual-channel promotion mechanism for management and technical staff to encourage employee development and retention[168] Future Outlook - The company provided a future outlook with a revenue guidance of 1.5 billion yuan for the next fiscal year, representing a 25% increase[146] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[146] - The company is considering strategic acquisitions to bolster its market position, with a budget of $100 million allocated for potential deals[147] - The company aims to improve operational efficiency, targeting a 5% reduction in costs through process optimization[150]

株洲千金药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2022 年第三季度报告 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 证券代码：600479 证券简称：千金药业 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | 经营活动产生的现金流 | 不适用 | 不适用 | 426,271,591.71 | | 13.94 | | --- | --- | --- | --- | --- | --- | | 量净额 | | | | | | | 基本每股收益（元/股） | 0.1685 | -17.68 | 0.4355 | | -3.67 | | 稀释每股收益（元/股） | 0.1685 | -17.68 | 0.4355 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,910,728,679.15, representing an increase of 8.94% compared to CNY 1,753,905,973.27 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was CNY 114,749,046.25, up 10.83% from CNY 103,540,054.87 in the previous year[18]. - The net cash flow from operating activities increased by 18.20%, reaching CNY 257,036,549.98 compared to CNY 217,456,354.26 in the same period last year[18]. - The basic earnings per share for the first half of 2022 was CNY 0.2670, a 7.92% increase from CNY 0.2474 in the previous year[19]. - The diluted earnings per share also stood at CNY 0.2670, reflecting the same growth rate of 7.92%[19]. - The weighted average return on net assets increased to 5.29%, up by 0.82 percentage points from 4.47% in the previous year[19]. - The total profit reached 162 million yuan, an increase of 10.81% compared to the previous year[42]. - The net profit attributable to shareholders was 115 million yuan, reflecting a growth of 10.83% year-on-year[42]. Assets and Liabilities - The total assets of the company at the end of the reporting period were CNY 4,138,432,110.25, a 1.93% increase from CNY 4,060,240,974.36 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company decreased by 5.94%, amounting to CNY 2,022,575,004.29 compared to CNY 2,150,385,209.84 at the end of the previous year[18]. - Total liabilities rose to CNY 1,576,529,913.60, compared to CNY 1,360,309,325.05, indicating an increase of 15.9%[114]. - The company's equity decreased to CNY 2,561,902,196.65 from CNY 2,699,931,649.31, a decline of 5.1%[114]. Research and Development - In the first half of 2022, the company obtained 12 new patents, including 9 invention patents and 3 design patents, bringing the total to 388 valid patents[24]. - The company is actively conducting clinical research projects, with several ongoing studies showing good progress[39]. - The company is increasing R&D investment to mitigate risks associated with long development cycles and low approval rates for new drugs[64]. Market and Industry Trends - The pharmaceutical industry in China saw a sales growth of 7.2% in 2021, with public medical institutions' drug sales reaching 1,297.3 billion[31]. - Online pharmacy sales in China surged to 223.4 billion in 2021, a significant increase of 40.2% year-on-year[32]. - The pharmaceutical industry is characterized as a weak cyclical industry, with steady growth driven by factors such as aging population and rising income levels[33]. - The company is adapting to industry challenges posed by policies like volume-based procurement and is focusing on the development of traditional Chinese medicine[32]. Environmental Management - The company operates two wastewater treatment plants with a total designed capacity of 2,000 tons/day, including 1,500 tons/day at the East River plant and 500 tons/day at the West River plant[76]. - The company has installed online monitoring systems for wastewater at its facilities, ensuring real-time data upload to government platforms[78]. - The company has implemented a pollution discharge quota management system, effectively reducing discharge volumes[81]. - The company has committed to third-party monitoring for its wastewater treatment operations to ensure compliance with environmental standards[78]. Corporate Governance and Shareholder Information - The company granted 11.3 million restricted shares to 144 incentive targets in February 2022, increasing the total shares from 418,507,117 to 429,807,117[97]. - The largest shareholder, Zhuzhou State-owned Assets Investment Holding Group Co., Ltd., holds 119,381,136 shares, representing 27.78% of total shares[103]. - Total number of common shareholders reached 51,580 by the end of the reporting period[101]. - The company reported no changes in the controlling shareholder or actual controller during the reporting period[108]. Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[5]. - The company faces risks related to fluctuations in traditional Chinese medicine prices, which are influenced by environmental factors and market speculation[61]. - Quality risks in pharmaceuticals include management and inherent risks, affecting the entire process from procurement to patient use[62]. Future Outlook - The company plans to focus on market expansion and new product development in the upcoming quarters[135]. - Future guidance indicates a cautious outlook with expectations of gradual recovery in the second half of 2022[135]. - The company is exploring potential mergers and acquisitions to enhance its market position[135].

Financial Performance - The company's operating revenue for Q1 2022 was ¥952,803,503.92, representing a year-on-year increase of 4.44%[5] - The net profit attributable to shareholders for the same period was ¥39,977,477.56, reflecting a growth of 5.43% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses decreased by 3.38% to ¥35,691,975.65[5] - Basic earnings per share for Q1 2022 stood at ¥0.0930, an increase of 2.65%[6] - Total operating revenue for Q1 2022 was approximately ¥952.80 million, an increase of 4.9% compared to ¥912.28 million in Q1 2021[19] - Net profit for Q1 2022 reached approximately ¥51.05 million, representing a 11.4% increase from ¥45.74 million in Q1 2021[20] - The total profit for Q1 2022 was approximately ¥59.44 million, an increase of 10.4% from ¥53.59 million in Q1 2021[20] Cash Flow - The net cash flow from operating activities was negative at -¥89,031,314.87, a decline of 261.84% year-on-year[5] - The net cash flow from operating activities for Q1 2022 was negative at approximately -¥89.03 million, compared to a positive ¥55.01 million in Q1 2021[22] - Cash inflow from operating activities totaled 195,107,331.20 in Q1 2022, down 40.2% from 326,585,910.75 in Q1 2021[30] - Cash outflow from operating activities was 279,947,348.03 in Q1 2022, a decrease of 31.6% compared to 409,315,100.61 in Q1 2021[30] - The net cash flow from investing activities was 104,256,819.90 in Q1 2022, down 25.7% from 140,297,685.05 in Q1 2021[31] - Cash inflow from investing activities increased significantly to 445,802,549.80 in Q1 2022, compared to 198,771,224.76 in Q1 2021, marking a growth of 124.8%[31] - The net cash flow from financing activities was 48,590,000.00 in Q1 2022, compared to 0.00 in Q1 2021, indicating a new source of cash inflow[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,182,747,417.59, up 3.02% from the end of the previous year[6] - The total liabilities as of March 31, 2022, were CNY 1,431,758,107.61, compared to CNY 1,360,309,325.05 at the end of 2021, marking an increase of about 5.2%[16] - The total equity attributable to shareholders increased to CNY 2,190,368,512.89 from CNY 2,150,385,209.84, reflecting a growth of approximately 1.9%[16] - The company's total current assets reached CNY 1,968,347,688.81 as of March 31, 2022, compared to CNY 1,882,965,787.77 at the end of 2021, marking an increase of about 4.54%[25] - The total liabilities as of March 31, 2022, were CNY 951,766,307.46, up from CNY 890,795,057.83 at the end of 2021, which is an increase of approximately 6.84%[26] Receivables and Inventory - Accounts receivable increased by 69.47% primarily due to changes in the company's credit policy[9] - Other receivables surged by 337.37% mainly due to increased advances and guarantees[9] - Accounts receivable rose significantly to CNY 379,156,692.29 from CNY 223,724,517.58, representing an increase of approximately 69.5%[14] - The company's inventory decreased to CNY 515,093,770.82 from CNY 547,778,902.92, showing a decline of about 6.0%[14] - The company reported a decrease in accounts receivable from CNY 156,148,871.64 in Q1 2021 to CNY 125,179,397.20 in Q1 2022, a decline of about 19.87%[25] Research and Development - The company incurred research and development expenses of approximately ¥25.17 million in Q1 2022, slightly down from ¥26.93 million in Q1 2021[19] - Research and development expenses for the first quarter of 2022 were CNY 11,862,895.56, slightly higher than CNY 11,115,757.65 in the first quarter of 2021, showing an increase of about 6.71%[27] Financial Position - The weighted average return on equity increased by 0.18 percentage points to 1.84%[6] - The company's retained earnings increased to CNY 970,711,015.00 from CNY 930,733,537.44, reflecting a growth of about 4.3%[16] - The company's short-term borrowings were CNY 66,358,031.52, a slight decrease from CNY 67,085,909.99, reflecting a reduction of about 1.1%[15] - The company's financial expenses showed a significant improvement, with a net financial income of CNY 1,388,845.30 in Q1 2022 compared to a loss of CNY 4,840,184.79 in Q1 2021[27] Accounting Standards - The company has not applied the new accounting standards starting from 2022, indicating a potential impact on future financial reporting[32]

Financial Performance - In 2021, the company's operating revenue reached CNY 3,663,844,613.10, representing a 1.02% increase compared to CNY 3,626,966,808.62 in 2020[24]. - The net profit attributable to shareholders of the listed company for 2021 was CNY 302,063,356.49, an increase of 1.68% from CNY 297,071,596.93 in 2020[24]. - The total profit for 2021 was CNY 433.42 million, reflecting a 2.08% increase compared to CNY 424.58 million in the previous year[54]. - The company achieved a total profit of 433 million yuan in 2021, an increase of 2.08% year-on-year[35]. - The company’s tax revenue reached 343 million yuan, up 5.93% compared to the previous year[35]. - The weighted average return on equity was 13.68%, an increase of 0.31 percentage points from the previous year[26]. - The company reported a net profit margin of 15%, which is an improvement from 12% in the previous year[145]. - The company reported a revenue of 1.5 billion yuan for the fiscal year 2021, representing a year-over-year growth of 15%[150]. Assets and Liabilities - The net assets attributable to shareholders of the listed company decreased by 5.13% to CNY 2,150,385,209.84 at the end of 2021, down from CNY 2,266,771,588.79 at the end of 2020[25]. - The total assets of the company at the end of 2021 were CNY 4,060,240,974.36, a decrease of 3.98% from CNY 4,228,711,385.05 at the end of 2020[25]. - The company’s total accounts receivable have been continuously decreasing, and the collection cycle is shortening, effectively reducing receivable risks[107]. Cash Flow - The cash flow generated from operating activities in 2021 was CNY 485,573,058.95, a decrease of 10.47% compared to CNY 542,373,092.58 in 2020[24]. - Net cash flow from operating activities decreased by 10.47% to CNY 485,573,058.95, primarily due to a reduction in the net amount of receivables from subsidiary Qianjin Pharmacy[72]. - Net cash flow from investing activities increased by 918.21 million yuan year-on-year, primarily due to higher cash payments for structured deposits in the previous period[57]. - Net cash flow from financing activities decreased by 416.34 million yuan year-on-year, mainly due to increased cash dividends and repayment of short-term loans[57]. Research and Development - R&D expenses increased by 4.48% to CNY 108.72 million, indicating a commitment to innovation and product development[56]. - The company has developed 5 new products with market potential, completed BE evaluations for 2 products, and achieved over 70% cost reduction in raw material production for certain drugs[37]. - The company has 401 valid patents, including 167 invention patents, which support its product quality and innovation[48]. - The company’s R&D investment amounted to 2.97% of its operating revenue, with a capitalized ratio of 8.45%[102]. - The company has 35 ongoing traditional Chinese medicine projects, including 5 pharmacological studies and 4 clinical trials for gynecological products[96]. Market Position and Strategy - The company is a leader in the female healthcare sector, with its flagship product, the Women's Health Capsule, being the top brand in the oral gynecological medicine category for over a decade[42]. - The company has established a full industry chain including pharmaceutical manufacturing, distribution, and traditional Chinese medicine cultivation[44]. - The company is actively expanding its product line into women's health and hygiene products, with initial sales of its specialized sanitary products showing promising growth[44]. - The company aims to enhance its core competitiveness by focusing on gynecological pharmaceuticals and expanding into women's health and derivative products[119]. - The company plans to strengthen its investment and acquisition strategies to enhance its industry chain and support its core business[120]. Corporate Governance - The board of directors and management have confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has maintained a stable management structure with no significant changes in the board composition during the reporting period[144]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, linking their income to the company's operational performance[138]. - The company has complied with legal requirements for corporate governance, ensuring equal rights for all shareholders, especially minority shareholders[136]. Environmental and Social Responsibility - The company has invested over 20 million yuan in social responsibility initiatives since 2011, including support for medical training and education[192]. - The "Hello, Qianjin" public welfare project has successfully conducted 772 health lectures by the end of 2021, with a total investment exceeding 8 million yuan, directly impacting over 1 million female participants[195]. - The company has implemented VOC control facilities to reduce emissions across its operations[191]. - Qianjin Pharmaceutical has no reported administrative penalties for environmental issues during the reporting period[189]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[145]. - New product launches are expected to contribute an additional 300 million in revenue in the upcoming year[145]. - The company is considering strategic acquisitions to enhance its market position, targeting firms with a combined revenue of 500 million[145]. - The company plans to implement a new digital marketing strategy, projected to increase customer engagement by 30%[150].

Financial Performance - The company's operating revenue for Q3 2021 was ¥914,153,174.08, a decrease of 6.11% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2021 was ¥85,665,257.72, an increase of 3.07% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥76,952,013.45, reflecting a year-on-year increase of 1.58%[5]. - The basic earnings per share for Q3 2021 was ¥0.2047, up by 3.07% compared to the same period last year[6]. - The net profit for Q3 2021 was CNY 221,231,213.16, an increase of 22.4% compared to CNY 180,785,515.98 in Q3 2020[20]. - The operating profit for Q3 2021 reached CNY 261,209,460.30, up from CNY 218,124,249.11 in the same period last year, reflecting a growth of 19.7%[20]. - The total comprehensive income for Q3 2021 was CNY 221,233,884.31, compared to CNY 180,803,099.79 in Q3 2020, indicating a growth of 22.4%[21]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥374,122,816.28, showing a significant increase of 54.54%[6]. - The net cash flow from operating activities for the first three quarters of 2021 was CNY 374,122,816.28, compared to CNY 242,094,209.04 in the same period last year, representing a growth of 54.5%[23]. - The company's cash and cash equivalents as of September 30, 2021, amounted to RMB 511,961,158.20, compared to RMB 755,373,935.15 at the end of 2020, reflecting a decrease in liquidity[15]. - The cash and cash equivalents at the end of Q3 2021 were CNY 345,024,550.00, a decrease from CNY 809,750,129.56 at the end of Q3 2020[23]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,073,409,727.47, a decrease of 3.67% from the end of the previous year[6]. - Total assets decreased to RMB 4,073,409,727.47 from RMB 4,228,711,385.05, indicating a contraction in the asset base[17]. - Total liabilities increased to RMB 1,526,986,881.25 from RMB 1,466,727,306.14, reflecting a rise in financial obligations[17]. - The company's equity attributable to shareholders decreased to RMB 2,037,498,104.95 from RMB 2,266,771,588.79, indicating a decline in shareholder value[18]. - Total current liabilities were CNY 1,377,761,196.37 as of the third quarter of 2021[27]. - Total liabilities amounted to CNY 1,466,727,306.14 as of the third quarter of 2021[27]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 37,107[12]. - The largest shareholder, Zhuzhou State-owned Assets Investment Holding Group Co., Ltd., held 28.5% of the shares[12]. - The equity attributable to shareholders at the end of the reporting period was ¥2,037,498,104.95, down by 10.11% compared to the previous year-end[6]. Operational Efficiency - The company reported a net profit margin improvement, with total operating costs decreasing while revenues remained stable, suggesting operational efficiency[19]. - Total operating costs for the first three quarters of 2021 were RMB 2,436,598,998.00, down from RMB 2,459,961,736.97 in the previous year, indicating a cost reduction strategy[19]. - The company reported a decrease in sales expenses to CNY 721,872,262.93 in Q3 2021 from CNY 717,829,103.61 in Q3 2020, reflecting a slight reduction of 0.4%[20]. - Research and development expenses increased to CNY 84,112,326.36 in Q3 2021 from CNY 76,558,798.95 in Q3 2020, showing a growth of 9.9%[20]. Future Growth Strategies - The company is focusing on enhancing its product offerings and market expansion strategies to drive future growth[19].

Group 1: Event Announcement - Zhuzhou Qianjin Pharmaceutical Co., Ltd. will participate in the "2021 Hunan Listed Companies Investor Online Collective Reception Day" [2] - The event aims to enhance interaction and communication with investors, allowing them to gain a deeper understanding of the company [2] - The online event will be held on September 24, 2021, from 15:00 to 16:55 [2] Group 2: Participation Details - Investors can join the event via the "Panorama Roadshow" website or by following the WeChat public account: Panorama Finance [2] - Company Secretary Ms. Zhu Li will communicate with investors online during the event [2] - The announcement emphasizes the company's commitment to accurate and complete information disclosure [2]